Introduction
Arrhythmogenic cardiomyopathy (AC) is an inherited heart muscle disorder characterized by progressive loss of cardiomyocytes coupled to fibro-fatty tissue replacement, typically beginning in the epicardium at the 'triangle of dysplasia' (right ventricular inflow tract, apex, and infundibulum) and progressing towards the endocardium. 1, 2 Clinical manifestations of AC include life-threatening ventricular arrhythmias, palpitations, syncope, and premature sudden cardiac death in young people and athletes. 1, 3 Unfortunately, in approximately one-fourth of patients the latter is the only manifestation of the disease. 4 While right ventricular dilation, aneurysms, and right heart failure are common features of the advanced disease, left ventricular involvement can be also found in AC late stages and occasionally can be predominant. 5, 6 About half of AC patients carry mutations in genes encoding the intercalated disc (ID)-mechanical junction proteins plakoglobin (JUP), desmoplakin (DSP), plakophilin-2 (PKP2), desmoglein-2 (DSG2), desmocollin-2 (DSC2), and aT-catenin. 7 Although rare, mutations in other genes, such as those encoding for cardiac ryanodine receptor type-2, transforming growth factor-b3, transmembrane protein 43/LUMA, desmin, titin, and lamin A/C have also been associated with AC. 8 Interestingly, in a significant proportion of patients compound heterozygous mutations in a single gene and digenic mutations (variants in two or more genes) are necessary to develop the ACM phenotype. 9, 10 Mechanical junctions in the ID consist of desmosomes and the hybrid junction area composita, which in itself comprises proteins of the genuine desmosomes and of the adherens junctions. Both structures are intercellular adhesive junctions that anchor intermediate filaments at the plasma membrane of neighbouring cardiomyocytes; by providing mechanical attachment between cells, they support the structural and functional integrity of the heart. 11, 12 Desmosomes also participate in intercellular signalling networks, of which the Wnt/b-catenin pathway is the most extensively studied. 13 In this context, it has been shown that suppression of desmoplakin expression leads to nuclear localization of the desmosomal protein Jup and to the reduction in the canonical Wnt/b-catenin signalling. 14 Moreover, two independent studies demonstrated that in inducible Jup cardiac-restricted knockout mice 15 and in cardiomyocyterestricted Jup knockout mice, 16 the ablation of plakoglobin led to b-catenin stabilization and overexpression. More recently, Swope et al. generated a conditional knockout allele for Jup, by introducing a neomycin cassette into the murine plakoglobin gene; such allele functions as a hypomorph when combined with a null allele. In this model, the authors reported no change in the activity of a b-catenin-controlled reporter gene in transgenic embryos, suggesting that an excess of b-catenin was not causing increased transcription of Wnt/b-catenin target genes. 17 MicroRNA (miRNA) dysregulation has been shown to play a role in the aetiology of multiple kinds of heart pathologies. 18 Very recently, miRNAs have been shown to be altered also in AC; specifically, miR-21-5p, and miR-135b were found deregulated in human AC heart samples, 19 while miR-184 expression was increased in PKP2-deficient cell lines and murine AC models following perturbations in E2F1 pathway. 20 Moreover, the induction of miR-130a overexpression in mouse has been associated with Dsc2 down-regulation, ventricular fibrosis, and lipid accumulation. 21 In this study, we generated two transgenic murine models characterized by cardiomyocyte-specific overexpression of human DSG2, either wild type or carrying the truncating p.Q558* mutation we had previously detected in an AC patient. 22 Mice overexpressing the nonsense mutation showed overt cardiac abnormalities both at the morphological (histological and ultrastructural) and at the molecular level, with the reduction of Wnt/b-catenin signalling. Moreover, genome wide RNA-Seq revealed in AC transgenic hearts the up-regulation of miR-217-5p and miR-708-5p, along with a reduction of miR-499-5p. Hence, our new transgenic model further supports the role of Wnt/b-catenin signalling in AC pathogenesis and the contribution of dysregulated miRNAs in the development of this disease.
Methods
For more detailed methods, see Supplementary material online.
Generation of the transgenic mice overexpressing human DSG2
Wild type (WT) human DSG2 (hDSG2) cDNA was obtained from a not-for-profit repository (Addgene, plasmid 32232). In order to introduce the DSG2 c.1672C>T (p.Q558X) nonsense mutation, the cDNA was amplified with the following primers: Fwd 5 0 -CCAGTCGACGCCACCATGGCGCGGAGCCC-3 0 (containing an optimized Kozak sequence preceded by the SalI restriction site for subsequent sub-cloning); Rev 5 0 -GGGAAGCTTTCAGCTAGTT ACTTATCGTCGTC-3 0 (containing three stop codons in the three different frames). Full-length WT and mutant hDSG2 cDNAs (3.4 and 1.7 kb, respectively) were cloned into a mammalian expression vector (kindly supplied by J. Robbins, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA) under the control of the cardiac-specific mouse a-myosin heavy chain (a-MyHC) promoter and tagged at the C-terminus with the FLAG sequence ( Figure 1A and B) . The 9.6 kb and 8.0 kb DNA expression cassettes were then linearized using the restriction enzyme NotI, purified and injected into B6D2F1xB6D2F1 fertilized mouse oocytes; treated embryos were transferred into pseudopregnant CD1 female mice. The resulting transgenic mice were then bred with C57BL/6NCrl animals, in order to establish and maintain transgenic lines. Transgene integration was confirmed by DNA dot blot analysis on genomic mouse DNA (see Supplementary material online, Figure S1 ).
In all four transgenic lines (Tg-hWT11, Tg-hWT40, Tg-hQ10, and TghQ13), litters were routinely genotyped by PCR with genomic DNA prepared from tail biopsies, using a pair of primers mapping inside the aMyHC promoter (Fwd 5 0 -CGGCACTCTTAGCAAACCTC-3 0 ) and downstream the start codon of hDSG2 cDNA (Rev 5 0 -
All experiments were performed in compliance with 2010/63/EU bylaw; procedures were approved by the local and the national animal research ethics committees (IACUC approval number 68/ 2011).
Western blot analysis
Upon sacrifice by cervical dislocation, hearts were harvested and pulverized by grinding in liquid nitrogen. Samples were then lysed in a modified RIPA buffer and resolved in 4-12% Bis-Tris PAGE gels before being transferred and immunoblotted. At least five independent western blot experiments were performed for each antibody; see Supplementary material online for details on used antibodies. Membranes were imaged with the Alliance 9.7 Imaging System (UVItec Limited) and quantitative densitometry was performed with the ImageJ software (https://imagej. nih.gov/ij/).
Immunofluorescence staining of heart tissue
Hearts were isolated and fixed in 1% paraformaldehyde in PBS at room temperature for 15 min, equilibrated in 30% sucrose overnight at 4 C, embedded in OCT and snap-frozen in liquid nitrogen prior to cryo-sectioning (8 lm). Images were acquired using a Zeiss LSM700 confocal microscope.
Histological analysis
Diastolic hearts, obtained by injection of 1 M KCl, five mice per line were collected at different ages (3-, 6-, and 12-month-old), fixed in 4% paraformaldehyde, dehydrated, and embedded in paraffin. Global heart architecture was determined from longitudinal 7-lm sections de-paraffinized, serially cut and stained by haematoxylin and eosin to examine the Wnt signalling and miRNA involvement in AC myocardium, by Azan Mallory for assessment of fibrosis, and by von Kossa for the detection of calcium deposits.
Ultrastructural analysis
For transmission electron microscopy (TEM) analysis, heart samples obtained from 3-and 6-month-old control and transgenic mice (Tg-hWT and Tg-hQ13) were treated with uranyl acetate and in OsO 4 and embedded in epoxy resin. Ultra-thin sections were then imaged and used to quantify the specified morphological features using iTEM software (Olympus SYS, Germany).
RNA isolation and sequencing
Total RNA was extracted from right and left ventricles, separately, using TRIZOL reagent according to the manufacturer's protocol (Invitrogen). For subsequent RNA sequencing, samples were sent to Exiqon, where the small RNA fraction of 3 Tg-hQ13 mice and three non-transgenic 6-month old mice was isolated by gel extraction and libraries were prepared using the NEBNext V R Multiplex Small RNA Library Prep Set for Illumina V R kit. The library yield was quantified on Agilent Bioanalyzer DNA1000 chips and samples were sequenced on an Illumina HiSeq 2000 platform, while base-calling was performed using the bcl2fastq 2.0 Conversion Software from Illumina. In total, 12 fastq files (n = 6 for transgenic mice and n = 6 for non-transgenic mice) were generated for bioinformatics analysis.
Quality control and alignment of reads to the mouse genome
FASTQC (http://www.bioinformatics.bbsrc.ac.uk/projects/fastqc/) and FASTX (http://hannonlab.cshl.edu/fastx_toolkit/) were used for quality control of fastq files; the Trimmomatic software was used to carry out 3 0 adapter clipping of reads, while Tophat2 software was used for alignment to the mouse genome (build: mm10, GRCm38, December 2011).
Differential expression analysis
Differential expression analysis was performed using the R Bioconductor package, DESeq2. Only miRNAs passing a fold-change (log2) cut-off of 1.2, together with a False Discovery Rate (FDR) cut-off of 0.05, were deemed to be differentially expressed to a statistically significant extent.
Target prediction and pathway analysis
The DNA Intelligent Analysis (DIANA)-micro T-CDS prediction algorithm and the DIANA-miRPath algorithm 23, 24 were used for target prediction of differentially expressed miRNAs. Mining of MiRTarBase
25
(http://mirtarbase.mbc.nctu.edu.tw) was performed to identify experimentally validated target for the miRNAs of interest.
Retrotranscription and real time PCR
RNA from right and left ventricles of non-transgenic and transgenic mice (five hearts per mouse type) was retrotranscribed using Universal cDNA synthesis kit II (Exiqon) and amplified with hsa-miR-708-5p miRCURY LNA miRNA PCR Assay (339306, Qiagen), mmu-miR-217-5p miRCURY LNA miRNA PCR Assay (339306, Qiagen), hsa-miR-499a-5p miRCURY LNA miRNA PCR Assay (339306, Qiagen), or 5S rRNA(hsa) miRCURY LNA miRNA PCR Assay PCR primer set, UniRT (339306, Qiagen) according to manufacturer's instructions. All amplification reactions were carried out in triplicate. Relative quantification was obtained using the 2 -DDCt method, normalized to the amount of endogenous control (5S).
Statistical analyses
The results are presented as mean ± standard error of the mean. Statistical analyses were performed using Prism software (Version 6, GraphPad Software Inc.), and consisted of ANOVA followed by Student's t-test when comparing two experimental groups. Differences were considered significant when P < 0.05.
Results from differential miRNA analysis and pathway enrichment analysis were hierarchically clustered and visualized using the R bioconductor package, gplots (R Foundation for Statistical Computing, Vienna, Austria); statistical analyses were performed in R, using the parameters described in Supplementary material online.
Results

Generation of Tg-hWT and Tg-hQ transgenic mice
To examine the contribution of DSG2 mutations to the development of AC phenotype in vivo, we generated and maintained transgenic mice with cardiomyocyte-specific overexpression of FLAG-tagged WT and mutant hDSG2, in the presence of normal levels of endogenous Dsg2. The p.Q558* nonsense mutation leads to the production of a truncated protein lacking transmembrane and intracellular domains ( Figure 1C) . Four independent transgenic lines were generated: two overexpressing normal hDSG2 (Tg-hWT11 and Tg-hWT40), and two overexpressing the truncated hDSG2 (Tg-hQ10 and Tg-hQ13). Dot blot experiments showed that three lines, Tg-hWT40, Tg-hQ10 and Tg-hQ13, had a high transgene copy number (>40 integrations), whereas one, Tg-hWT11, had less than 3 integrated copies (Supplementary material online, Figure  S1 ). Western blot analysis confirmed transgene expression in the heart ( Figure 1D) ; at the same time, no hDSG2 could be detected in smooth muscle, brain, and kidney, thus confirming cardiac tissue-specific expression of the transgene (Supplementary material online, Figure S2 ). Mutant mice were backcrossed to C57BL/6N for 9 generations.
Importantly, a proper localization of hDSG2 to the IDs was seen in TghWT mice, whereas both Tg-hQ10 and Tg-hQ13 cardiomyocytes showed a cytoplasmic accumulation of the truncated protein ( Figure 1E-H") .
As expected, neither WT transgenic lines showed any clinical signs of cardiomyopathy. Amongst the two lines carrying the truncated protein, Tg-hQ10 exhibited an increased incidence of sudden death starting at nine months of age when compared with control littermates (at 12 months, survival rate of Tg-hQ10 mice was 65%, whereas it was 80% in controls; data not shown). Such phenomenon was not present in the Tg-hQ13 line. Tg-hQ10 mice were also affected by small litter size and poor survival rate at weaning, which led to the loss of the line during the study.
Echocardiography was performed in 12-month-old animals. Tg-hQ mice exhibited statistically significant thinning of the right ventricle anterior wall when compared with Tg-hWT (Supplementary material online, Table S1 ). No alterations in either structure or function of the left ventricle were observed. Telemetric electrocardiogram analyses in conscious mice revealed only sporadic ventricular extra systoles.
Histological phenotype in transgenic hearts
Hearts from transgenic animals were studied by histology, immunohistochemistry, and TEM. Gross morphological examination of the hearts of non-transgenic and Tg-hWT mice did not reveal any pathological
changes in mice from 2 to 12 months. Tg-hQ mice, on the other hand, showed no visible histological alterations for the first 9 months, but at 12 months of age both Tg-hQ strains exhibited, albeit with interindividual variability, typical AC pathological changes, namely loss of cardiomyocytes and signs of fibrosis in both ventricles (Figure 2 and Supplementary material online, Figure S3) .
TEM analysis, which was carried out in hearts from 3-and 6-monthold Tg-hWT and Tg-hQ13 animals, showed that the latter exhibited clear ultrastructural anomalies at 6 months of age. Specifically, in Tg-hQ cardiomyocytes, sarcomeres were less densely packed than in controls, due to a marked dilation of the sarcoplasmic reticulum, and IDs exhibited an overall lower number of desmosomes ( Figure 3A-C) . Morphometric analysis of desmosomes also revealed a significant decrease of their length in Tg-hQ mice ( Figure 3D) . Cardiomyocytes of Tg-hQ mice also exhibited enlarged cisternae of endoplasmic reticulum (suggesting the partial retention of the mutant protein in the endoplasmic reticulum) and some mitochondrial swelling ( Figure 3A) . Finally, Tg-hQ cardiomyocytes contained an increased number of vesicle budding profiles at their membranes in the IDs ( Figure 3E ). This latter finding is in agreement with previous papers showing the presence of vesicles of various sizes in areas of dissociation of IDs, derived from swelling of the plasma membrane processes, in patients with congestive cardiomyopathy of unknown origin or polymyositis and congestive cardiomyopathy and in an ovine tachypacing-induced heart failure model. Given that recent lines of evidence suggest that the pathogenesis of AC is related to the alteration of Wnt signalling (see 28 for a recent review),
we decided to investigate the potential involvement of such pathway in our Tg-hQ animals. To this aim, we analysed a number of Wnt-related proteins in transgenic and non-transgenic hearts harvested from 3-and 6-month-old animals; specifically, by western blot we quantified the relative amounts of b-catenin, its de-phosphorylated active form (ABC), JUP, c-Fos, c-Myc, Cyclin-D1. The relative expression level of both b-catenin and JUP proteins appeared unchanged between transgenic and control hearts. However, a reduction of ABC in both Tg-hQ lines was found at 3 and 6 months, indicating a significant change in b-catenin regulation in the presence of a truncated form of hDSG2 since an early age ( Figure 4 and Supplementary material online, Figures S4 and S5) . Importantly, a comparable decrease was found in Tg-hQ hearts for two of its downstream targets, namely c-Fos, and cyclin-D1 ( Figure 4 and Supplementary material online, Figure S4 ).
Deep sequencing and identification of differentially expressed cardiac miRNA
To identify possible cardiac miRNAs dysregulation in AC transgenic mice, RNA-Seq was performed in myocardial samples from right and left ventricles from non-transgenic controls and Tg-hQ13 mice of 6 months of age. Comparison of miRNAs expression levels was performed as follows: left Tg-hQ13 ventricles vs. left control ventricles; right Tg-hQ13 ventricles vs. right control ventricles; left ventricles vs. right Tg-hQ13 ventricles; left ventricles vs. right ventricles from control hearts; left and right ventricles from Tg-hQ13 hearts vs. left and right ventricles from non-transgenic hearts. miRNAs passing three distinct cut-offs (Log2 fold change ± 1.2, P-value <0.05 and adjusted P-value <0.05) were considered to be differentially expressed to a significant extent. While no significant differences were observed in the left vs. right ventricles comparison in non-transgenic hearts, a total of 31 miRNAs resulted differentially expressed in at least one of the other four comparisons. Such significant changes were largely driven by the differences in transgenic vs. nontransgenic left ventricles as well as transgenic vs. non-transgenic right ventricles ( Figure 5 ). In particular, 24 miRNAs were altered in Tg-hQ13 hearts compared with non-transgenic hearts, 18 upregulated and 6 down-regulated, while 7 miRNAs were found significantly altered when comparing right vs. left ventricle of transgenic mice. In order to prioritize the altered miRNAs, we focused on the most up-and down-regulated in transgenic hearts vs. non-transgenic hearts, highly conserved among different species (i.e. at most one mismatch between human, rat, mouse, macaca mulatta, and chimpanzee), and we excluded -3p miRNAs, which are more frequently secreted than -5p miRNAs. By applying these filters, we determined four prioritized 
miRNAs: miR-499-5p (Log2 fold change: -2,9), miR-216a-5p (Log2 fold change: 8,00), miR-217-5p (Log2 fold change: 8,08), and miR-708-5p (Log2 fold change: 6,87). Real-time PCR was then used to confirm the over/under-expression of these four miRNAs, not only between Tg-hQ13 and non-transgenic mice, but also between Tg-hQ13 and Tg-hWT40. These analyses confirmed that miR-217-5p, miR-708-5p, and miR-499-5p were altered when comparing Tg-hQ13 with either non-transgenic and Tg-hWT40 ( Figure 6 ). On the other hand, miR-216a-5p resulted to be up-regulated when considering non-transgenic vs. Tg-hQ13 but not when comparing Tg-hWT40 vs. Tg-hQ13 and was hence excluded from further analysis (not shown). 
Target genes for up-and down-regulated AC miRNAs
In order to predict targets of miR-217-5p, miR-708-5p, and miR-499-5p, we performed an in silico analysis using the DIANA-micro T-CDS and DIANA-miRPath prediction algorithms. Interestingly, in agreement with the phenotype observed in Tg-hQ hearts (i.e. reduction of Wnt/b-catenin signalling, widening of actin filaments and reduction in desmosome size and length), target prediction for the selected miRNAs identified candidate target genes involved in the regulation of the Wnt/b-catenin signalling, adherens junctions and gap junctions ( Figure 7 and Table 1) .
Furthermore, we interrogated miRTarBase, the validated microRNAtarget interactions database, 25 identifying numerous experimentally validated targets of the three dysregulated miRNAs (Table 1) . Notably, several validated target genes are associated with Wnt/b-catenin pathway ( Table 1) . In particular, PTEN and SOX6 have been experimentally validated as miR-217-5p and miR-499-5p targets in cardiomyocytes.
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Figure 4 ß-catenin expression and signalling in transgenic mouse hearts. Examples of western blot analysis (A) and overall quantification (B) of ß-catenin (ß-CAT), active-ß-catenin (ABC), plakoglobin (PG), c-Fos, c-Myc, cyclin-D1, GSK3b, and pGSK3b protein levels. Whole heart lysates were from nontransgenic controls (NTG), transgenic wild type (TG WT), and transgenic mutated (TG Q) mice at 6 months of age (n = 5 for each group). In the instances in which one-way ANOVA analysis yielded P < 0.05, Student's t-test was used to perform pair-wise comparisons between the four experimental groups (*P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001).
Discussion
In this article, we describe for the first time the molecular pathway and the dysregulated miRNAs associated with a nonsense mutation (p.Q558*) in DSG2 in a transgenic model for AC. This mutation, previously found in an affected patient, 22 occurs in the extracellular anchor domain and results in a truncated protein lacking the transmembrane and the cytoplasmic domains. Overall, Tg-hQ animals overexpressing this mutation showed biventricular signs of fibrosis, abnormal IDs and a significant reduction in size and number of desmosomes, thus mimicking some major features of AC. TEM analyses also suggested the presence of other structural abnormalities involving actin filaments, endoplasmic reticulum and mitochondria. IDs abnormalities were already detectable at 6 months of age, whereas histological alterations became apparent at 12 months of age. Immunohistochemistry assays showed that the truncated protein in Tg-hQ mice is mainly localized into the cytoplasm and not at the cell-cell contacts, possibly leading to disruption of the proper cytoskeleton-sarcolemmal network and resulting in compromised adhesion. Indeed, structural defects, such as intercellular space widening at the ID, fibrous replacement, or absence of desmosome-like structures were previously observed in different DSG2 models lacking exons 4-6, or overexpressing the p.N271S mutation, 34, 35 as well as in the cardiomyocyte-specific Dsg2 heterozygous-knock out mouse. 36 Altogether, these different animal models emphasize the crucial adhesive role of desmoglein-2 in the heart and indicate that the loss of its proper function cannot be compensated by desmocollin-2. Our DSG2 mice provided further details about AC disease before macroscopic and microscopic alterations became apparent. In fact, while histological alterations became apparent at 12 months of age, we observed the reduction of the Wnt/ß-catenin signalling in 3-and 6-month-old Tg-hQ mice. While the down-regulation of this pathway was previously reported in other AC models lacking either Dsp or Pkp2 or overexpressing Jup, 14, 37, 38 it has never been associated with DSG2 mutations or loss. These findings further support the idea that the down-regulation of the canonical Wnt/ß-catenin signalling might be a common key event in the AC pathogenesis. However, further studies are required to establish the detailed mechanisms related to this reduction as well as whether and which additional pathways are involved in AC pathogenesis. In this context, important insights could arise from the miRNA profiling that we and other groups provided. Here, we report for the first time the genome-wide cardiac miRNA profiling in a novel AC transgenic mouse overexpressing a nonsense mutation in DSG2 gene consisting in the up-regulation of miR-217-5p and miR-708-5p and down-regulation of miR-499-5p, all highly conserved among different species. While the role of miR-499-5p in the heart has been extensively reported, the cardiac function of miR-217-5p had so far been associated with foetal gene Figure 6 Expression level and conservation of dysregulated miRNAs. Expression levels and conservation among different species for miR-217-5p, miR-708-5p, and miR-499-5p. Expression levels have been evaluated by real-time PCR in the left ventricles of 6-month-old mice, using the 2 DDCt method (n = 5 and 6, *P < 0.05). re-expression, together with decreased expression on the H3K9 dimethyltransferases EHMT1 and EHMT2, resulting in the reduction of euchromatic H3K9me2 and pathological cardiac hypertrophy. 39 Moreover, miR-217-5p was also associated with senescence and angiogenesis in endothelial and smooth muscle cells through the regulation of the expression of SIRT1. 40 MiR-708-5p has been widely associated with cancer, while only Deng et al. 41 reported its overexpression in H9C2 cells and neonatal cardiac rodent cells, which resulted in the increased cellular proliferation and myocardial regeneration in vivo and in the protection of cardiomyocytes against apoptosis through the inhibition of MAPK14 expression. As for miR-499, it has been described as a regulator of late cardiogenesis and shown to promote differentiation of myoblasts to cardiomyocytes through the down-regulation of myocyte enhancer factor 2C 42 or SRY box-6, a conserved transcription repressor known to inhibit slow-twitch myofiber-specific expression programme in zebrafish. 43 Moreover, miR-499 up-regulation has been linked both to the pathogenesis of heart hypertrophy through the regulation of the expression of sarcomeric genes 44 as well as to a possible cardioprotective role by targeting pro-apoptotic regulators such as Dyrk2, Pdcd4, Pasc2, Drp1. 43, 45, 46 Interestingly, miR-499 has also been shown to drive cardiac differentiation in rat bone marrow-derived mesenchymal stem cells through the Wnt/ß-catenin signalling activation. 47 In this study, our in silico analysis supports the involvement of miR-217-5p, miR-708-5p, and miR-499-5p in the reduction of the Wnt/b-catenin signalling in AC, as they are all predicted to target genes involved in this pathway. Furthermore, miR-499-5p and miR-708-5p were also predicted to target a conspicuous number of genes encoding for proteins of mechanical junctions, cytoskeleton, and gap junctions. These predictions are in agreement with the phenotypic features observed in our transgenic mice (i.e. reduction of the Wnt/ß-catenin signalling, widening of actin filaments, significant decrease of number and size of desmosomes). Importantly, some of these predictions have been already experimentally validated in cardiac models, as reported in MiRTarbase. PTEN was shown to be a target of miR-217-5p in an in vivo model of cardiac dysfunction. 29 In this study, the in vivo overexpression of miR-217-5p resulted in aggravated pressure overload-induced cardiac hypertrophy, fibrosis and cardiac dysfunction through the suppression of PTEN, a protein also involved in the regulation of the Wnt/b-catenin signalling pathway in the heart. 29 ,30 SOX6, a transcription factor known to interact with b-catenin, was also reported in MiRTarbase as an experimentally validated target of miR-499 in the heart. In this context, miR-499-5p promoted cardiac cell differentiation and proliferation in vitro, by directly targeting SOX6, thus resulting in the suppression of the canonical Wnt/bcatenin pathway. [31] [32] [33] While the above-mentioned reports lend support and they should be verified in our animal models. However, the identification of the exact mechanisms involving miR-217-5p, miR-708-5p, and miR-499-5p in AC is beyond the aim of this study and further efforts will be necessary to elucidate their role in the disease. Very recent studies have also reported the involvement of different miRNAs in AC. S-Poly (T) Plus analysis in human AC samples suggested that miR-21-5p and miR-135b are associated with cardiac fibro-adiposis in relation to Wnt and Hippo pathways. 19 Microarray analysis in Pkp2 knockdown in HL1 and cardiac mesenchymal progenitor cells detected a significant down-regulation of miR-184, which was determined by the suppression of E2F1 pathway and hypermethylation of the CpG sites at miR-184 promoter. 20 Finally, cardiomyocyte-specific inducible overexpression of miR-130a in a transgenic mouse correlated with Cx43 and desmocollin 2 reduction and AC phenotype. 21, 48 These miRNAs didn't result deregulated from our RNA-Seq analysis; such finding might derive from the use of genetically different AC models and/or from the use of different technical approaches for miRNA detection. AC phenotype is highly complex and it shows a wide variability, spanning from asymptomatic, to mild, to severe, including preferentially 'arrhythmic' or 'structural' forms of the disease. The different miRNA profiling observed in the different models might hence be also correlated to the different disease features. Further studies, including a broader number of samples associated with different gene mutations, will be necessary to elucidate this aspect.
Limitations
The transgenic model with cardiomyocyte-specific overexpression of mutant hDSG2 reported in this study presents some important limitations. The levels of transgene are much higher than what would be observed in a heterozygous mutant and, as this method of transgenesis does not allow for control site of integration, insertional mutagenesis is also possible. Moreover, the consequence of the expression of the p.Q558* nonsense mutation might not exactly reflect the situation present in the original patient, as we have introduced a shortened cDNA. This latter is expected to produce a stable truncated protein, while a full-length nonsense mRNA could be unstable.
Despite representing the most difficult strategy to develop a gene targeted mouse, knock-in models would be more informative, as they allow the introduction of exactly the specific genetic alterations occurring in patients. CRISPR (clustered regularly interspersed short palindromic repeats)/Cas9 (CRISPR associated protein 9) technique has recently emerged as the method of choice for producing mutations in animal models. The approach used in the present study provides important hints on the role of the mutated protein in the onset of pathological traits, but actual knock-in models will allow to better study the effects of such mutation.
In conclusion, our data provide novel insights to widen the study on AC pathogenesis. The validation of the targets of miR-217-5p, miR-708-5p, and miR-499-5p might yield not only mechanistic understanding of pathogenesis in AC, but may also suggest novel candidate disease genes.
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